PTC Therapeutics (PTCT)
RBC Capital analyst Brian Abrahams maintained a Sell rating on PTC Therapeutics on December 15 and set a price target of $45.00. The company’s shares closed last Wednesday at $64.73, close to its 52-week high of $66.51.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 9.0% and a 50.6% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
PTC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $64.75.
Gamida Cell (GMDA)
RBC Capital analyst Gregory Renza maintained a Buy rating on Gamida Cell on December 14 and set a price target of $12.00. The company’s shares closed last Wednesday at $8.45.
According to TipRanks.com, Renza is a 5-star analyst with an average return of 31.8% and a 63.6% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Inovio Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gamida Cell with a $14.80 average price target, implying a 60.7% upside from current levels. In a report issued on December 6, Oppenheimer also assigned a Buy rating to the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.